Treatment of Stage III Non-Small Cell Lung Cancer

If cost and reimbursement were not issues, which adjuvant therapy would you recommend off protocol for a 60-year-old nonsmoker with a good performance status and good lung function whom you are seeing postoperatively after complete resection (with negative margins) of pathologic Stage IIIA (T1-2, N2) nonsquamous NSCLC, assuming the patient has no medical contraindications to any of the treatment choices?

For potentially resectable Stage IIIA, N2-positive NSCLC in a patient with a good performance status:

For nonbulky Stage IIIA, N2-positive NSCLC in a patient with a good performance status, my most common treatment approach is:

Are you aware of the updated clinical trial results evaluating the safety and efficacy of docetaxel consolidation chemotherapy presented at the 2007 ASCO meeting?

If yes, to what extent do you believe these results will influence your use of docetaxel consolidation chemotherapy?*

For a patient with unresectable Stage IIIB NSCLC treated with concurrent chemoradiation therapy, would you recommend docetaxel consolidation chemotherapy?

Percent of practicing oncologists who would recommend docetaxel consolidation, based on awareness of updated trial results: